GlassScriptPhysician profile
Nora A Phillips
NPI 1487239323
$2,751.64
in general payments reported to CMS, 2019-2025
11 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $285 · 2022: $654 · 2023: $914 · 2024: $396 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,282.00 | 2022-2025 | |
| Galderma Laboratories, L.P. | $616.85 | 2021-2025 | |
| Novo Nordisk INC | $445.66 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $175.06 | 2023 | Veozah |
| Lilly USA, LLC | $48.36 | 2024 | Olumiant, Taltz, Zepbound |
| Ipsen Biopharmaceuticals, INC | $46.09 | 2023 | Dysport |
| Pfizer INC. | $43.55 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.54 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $24.96 | 2023 | Gvoke Hypopen |
| Revance Therapeutics, INC. | $17.54 | 2024 | Daxxify |
| Coopersurgical, INC. | $13.03 | 2023 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.